These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 16723569

  • 1. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.
    Hirt D, Treluyer JM, Jullien V, Firtion G, Chappuy H, Rey E, Pons G, Mandelbrot L, Urien S.
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2079-86. PubMed ID: 16723569
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
    Crommentuyn KM, Scherpbier HJ, Kuijpers TW, Mathôt RA, Huitema AD, Beijnen JH.
    Pediatr Infect Dis J; 2006 Jun; 25(6):538-43. PubMed ID: 16732153
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum.
    van Heeswijk RP, Khaliq Y, Gallicano KD, Bourbeau M, Seguin I, Phillips EJ, Cameron DW.
    Clin Pharmacol Ther; 2004 Dec; 76(6):588-97. PubMed ID: 15592330
    [Abstract] [Full Text] [Related]

  • 7. Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.
    Hirt D, Mentré F, Tran A, Rey E, Auleley S, Salmon D, Duval X, Tréluyer JM, COPHAR2- ANRS Study Group.
    Br J Clin Pharmacol; 2008 Apr; 65(4):548-57. PubMed ID: 17922881
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.
    Panhard X, Goujard C, Legrand M, Taburet AM, Diquet B, Mentré F, COPHAR 1-ANRS study group.
    Br J Clin Pharmacol; 2005 Oct; 60(4):390-403. PubMed ID: 16187971
    [Abstract] [Full Text] [Related]

  • 10. Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.
    Brendel K, Legrand M, Taburet AM, Baron G, Goujard C, Mentré F, Cophar 1-ANRS 102 Trial Group.
    Fundam Clin Pharmacol; 2005 Jun; 19(3):373-83. PubMed ID: 15910662
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.
    Payen S, Faye A, Compagnucci A, Giaquinto C, Gibbs D, Gomeni R, Bressolle F, Jacqz-Aigrain E.
    Antimicrob Agents Chemother; 2005 Feb; 49(2):525-35. PubMed ID: 15673728
    [Abstract] [Full Text] [Related]

  • 13. Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.
    Stocker H, Herzmann C, Breske A, Kruse G, Berger M, Schulbin H, Hill A, Steinmüller J, Becker M, Arastéh K, Kurowski M.
    J Antimicrob Chemother; 2007 Mar; 59(3):560-4. PubMed ID: 17255144
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate.
    Boffito M, Pozniak A, Kearney BP, Higgs C, Mathias A, Zhong L, Shah J.
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4386-9. PubMed ID: 16189129
    [Abstract] [Full Text] [Related]

  • 16. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.
    Colombo S, Buclin T, Cavassini M, Décosterd LA, Telenti A, Biollaz J, Csajka C.
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3801-8. PubMed ID: 16940065
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children.
    Gatti G, Castelli-Gattinara G, Cruciani M, Bernardi S, De Pascalis CR, Pontali E, Papa L, Miletich F, Bassetti D.
    Clin Infect Dis; 2003 Jun 01; 36(11):1476-82. PubMed ID: 12766843
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.
    Bryson YJ, Mirochnick M, Stek A, Mofenson LM, Connor J, Capparelli E, Watts DH, Huang S, Hughes MD, Kaiser K, Purdue L, Asfaw Y, Keller M, Smith E, PACTG 353 Team.
    HIV Clin Trials; 2008 Jun 01; 9(2):115-25. PubMed ID: 18474496
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.